8VC’s David Moskowitz and Daniel Haders discuss the Bio-IT space and why 8VC invested in Model Medicines
From Research to Investing
In Episode 1 of our four-part series on finding the right moment to act, and when the moment chooses you. David talks about how being in the right place, at the right time, with the right mindset enabled his professional ascension from research to investing.
8VC's Bio-IT Investments
In Episode 2 of our four-part series to discuss 8VC's Bio-IT investments; and why the firm values operating experience and action, but also new ideas and creative theories. David will touch on the firms unique blend of strengths and worldviews, and how this enables 8VC to model investment opportunities using multiple frameworks to help companies succeed in unparalleled ways.
8VC's Investment in
Model Medicines
In Episode 3 of our four-part series to talk about why 8VC invested in Model Medicines, and how their approach to drug discovery and development – one built on fundamental chemistry – fits within 8VC's overall Bio-IT investment portfolio. The two will dive deep into the company’s vision; highlight recent partnerships; and the successes they’ve had along the way.
AI and the Future of
Drug Discovery
In the final episode of our four-part series in our discussion with David Moskowitz of 8VC, Daniel Haders II, Ph.D. asks David to describe how he sees the future of AI in drug discovery unfolding, and more broadly, what impact does AI and machine learning have on the pharmaceutical sector writ large.
“By partnering with Bio-IT pioneers, like Model Medicines, we can work together to generate incredible value while improving lives.”
David Moskowitz
Principal, 8VC
8VC Bio-IT
8VC believes tremendous opportunities are emerging for entrepreneurs, scientists, and engineers who can harness data-driven biology. They will be able to bring biomedicine from bench to body by measuring large amounts of biological data, analyzing these data with informatics, and modulating living systems through bioengineering. The measure, analyze, modulate process allows technologists to effectively wield novel biomedical techniques to create cutting-edge products and solutions.
David Moskowitz
David Moskowitz focuses on the Bio-IT space. Prior to joining 8VC, David completed his Ph.D. in Biomedical Informatics at Stanford University, where he concurrently received an M.S. in Statistics. His research focused on the development of statistical and machine learning approaches for analyzing genomics data, and the characterization of epigenetic changes associated with aging in T cells. Previously, David was a Bioinformatic Analyst at Einstein College of Medicine, where he worked on the genetics of aging and human disease. He performed his undergraduate studies in Computational Biology at Brown University.